Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
14Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Viridian Therapeutics, Inc. (VRDN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
23Total relationships
3Distinct source URLs
7High confidence
0.762Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Viridian Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
WUXI-BIOLOGICS-HONG-KONG-LIMITED
WUXI-BIOLOGICS-HONG-KONG-LIMITED
92%
WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use
Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC g…
Reciprocal relationship from XNCR graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR g…
Reciprocal relationship from ZBIO graph: IL-17AA homodimer and IL-17AF heterodimer signaling. We expect Phase 1 clinical study initiation in 2026. ZB022 is an oral, brain-penetrant tyrosine kinase 2 …
PARAGON-THERAPEUTICS-INC
PARAGON-THERAPEUTICS-INC
70%
In January 2022, the Company and Paragon Therapeutics, Inc. (“Paragon”) entered into an antibody and discovery option agreement.
Viridian Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ZAI-LAB
ZAI-LAB
90%
In August 2025, the Company entered into a material transfer agreement (the “MTA”) with Zai Lab, to supply certain materials for clinical trial use in exchange for a fixed payment.
ZENAS-BIOPHARMA
ZENAS-BIOPHARMA
80%
The Side Agreement and MTA were evaluated under ASC 606, Revenue from Contracts with Customers, and determined to be contract modifications to the Zenas Agreements.
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require…
Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from CRNX g…
Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC g…
Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, we may require significant additional capital earlier than we currently expect under our present business plans. Loan and Security Agree…
Reciprocal relationship from JNJ graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from JNJ grap…
ts • substantial costs of litigation, including monetary awards to patients or other claimants; • liabilities that substantially exceed our product liability insurance, which we would then be require…
Reciprocal relationship from MYGN graph: Reciprocal relationship from VRDN graph: he development of our product candidates, our financial condition, results of operations and business prospects. In a…
he development of our product candidates, our financial condition, results of operations and business prospects. In addition, it may be difficult or impossible to obtain certain source documentation …
estimate of future cash flows includes estimated future Net Sales Royalties to be paid to DRI and the receipt of conditional payments from DRI that were deemed probable of achievement at inception. T…
Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO g…
HONG-KONG-LIMITED
HONG-KONG-LIMITED
62%
ndition, results of operations and growth prospects. We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, including Chinese manufacturer WuXi Biologic…
Reciprocal relationship from SLNG graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from SLNG graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from SLNG g…
Viridian Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
VRDN-DEBT-13423
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
VRDN-DEBT-13422
Warrants outstanding: 7535815
90%
xbrl warrant detail from xbrl 2025-12-31.
VRDN-DEBT
Debt stack $29.3M
90%
Market cache reports total debt of $29.3M.
Viridian Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Viridian Therapeutics, Inc..
Viridian Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
VRDN-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 227 tracked holders.
Viridian Therapeutics, Inc. Extended Supply Chain Network
